200 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Mizuho Bank Ltd.

Mizuho Bank Ltd. purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 200 shares of the company’s stock, valued at approximately $154,000. Eli Lilly and Company comprises 0.0% of Mizuho Bank Ltd.’s investment portfolio, making the stock its 20th largest holding.

A number of other large investors also recently bought and sold shares of LLY. Gladstone Capital Management LLP acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $18,142,000. Resona Asset Management Co. Ltd. purchased a new position in Eli Lilly and Company in the fourth quarter valued at $192,435,000. Pioneer Trust Bank N A OR raised its position in shares of Eli Lilly and Company by 17.2% in the fourth quarter. Pioneer Trust Bank N A OR now owns 10,754 shares of the company’s stock worth $8,302,000 after acquiring an additional 1,579 shares during the period. Leeward Financial Partners LLC boosted its stake in shares of Eli Lilly and Company by 51.9% during the 4th quarter. Leeward Financial Partners LLC now owns 6,422 shares of the company’s stock worth $4,958,000 after acquiring an additional 2,195 shares in the last quarter. Finally, Landscape Capital Management L.L.C. grew its position in shares of Eli Lilly and Company by 200.9% during the 4th quarter. Landscape Capital Management L.L.C. now owns 4,919 shares of the company’s stock valued at $3,797,000 after acquiring an additional 3,284 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $737.56 on Friday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market capitalization of $699.33 billion, a PE ratio of 62.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The business has a 50 day simple moving average of $848.36 and a 200-day simple moving average of $832.44.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Morgan Stanley set a $1,146.00 target price on Eli Lilly and Company in a research report on Thursday, March 6th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.